Skip to main content

Compare Stocks

Date Range: 

 Travere TherapeuticsApplied Molecular TransportArcutis BiotherapeuticsuniQureDiaMedica Therapeutics
Price Information
Current Price$18.27$44.70$25.75$32.44$6.50
52 Week RangeBuyBuyBuyBuyN/A
Overall Score1.
Analysis Score3.
Community Score2.
Dividend Score0.
Ownership Score0.
Earnings & Valuation Score0.
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyN/A
Consensus Price Target$42.67$68.75$54.67$68.46N/A
% Upside from Price Target133.53% upside53.80% upside112.30% upside111.04% upsideN/A
Trade Information
Market Cap$1.10 billion$1.58 billion$1.29 billion$1.49 billion$1.02 billion
Average Volume605,309227,360265,427464,697131,151
Sales & Book Value
Annual Revenue$175.34 millionN/AN/A$7.28 millionN/A
Price / Sales6.30N/AN/A205.06N/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.15 per shareN/AN/A$7.41 per shareN/A
Price / Book3.55N/AN/A4.38N/A
Net Income$-146,430,000.00$-28,040,000.00$-42,000,000.00$-124,200,000.00$-2,220,000.00
Trailing P/E RatioN/A0.00N/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
Net Margins-40.24%N/AN/A-2,738.33%N/A
Return on Equity (ROE)-29.27%N/A-81.74%-59.64%N/A
Return on Assets (ROA)-12.25%N/A-57.72%-41.47%N/A
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt-to-Equity Ratio0.71%N/AN/A0.16%N/A
Current Ratio6.60%19.39%9.18%8.62%N/A
Quick Ratio6.50%19.39%9.18%8.62%N/A
Ownership Information
Institutional Ownership PercentageN/A51.99%79.63%78.34%N/A
Insider Ownership Percentage4.63%N/AN/A2.79%N/A
Shares Outstanding60.46 million35.25 million50.21 million46.02 million157.14 million
Next Earnings Date7/29/2021 (Estimated)8/10/2021 (Estimated)8/10/2021 (Estimated)7/29/2021 (Estimated)N/A
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
5/7/2021Travere TherapeuticsBMO Capital MarketsLower Price Target
4/12/2021Travere TherapeuticsWedbushLower Price Target
3/3/2021Travere TherapeuticsSVB LeerinkReiterated Rating
2/3/2021Travere TherapeuticsCanaccord GenuityBoost Price Target
11/23/2020Travere TherapeuticsEvercore ISIInitiated Coverage
3/23/2021Applied Molecular TransportJefferies Financial GroupBoost Price Target
3/23/2021Applied Molecular TransportJMP SecuritiesInitiated Coverage
6/30/2020Applied Molecular TransportBank of AmericaInitiated Coverage
2/2/2021Arcutis BiotherapeuticsTruistBoost Price Target
2/1/2021Arcutis BiotherapeuticsCowenBoost Price Target
1/28/2021Arcutis BiotherapeuticsJonestradingInitiated Coverage
11/9/2020Arcutis BiotherapeuticsThe Goldman Sachs GroupUpgrade
3/20/2020Arcutis BiotherapeuticsCantor FitzgeraldReiterated Rating
2/25/2020Arcutis BiotherapeuticsGuggenheimInitiated Coverage
3/8/2021uniQureChardan CapitalBoost Price Target
12/22/2020uniQureRoyal Bank of CanadaBoost Price Target
12/21/2020uniQureHC WainwrightBoost Price Target
11/20/2020uniQureCredit Suisse GroupBoost Price Target
11/11/2020uniQureBerenberg BankInitiated Coverage
8/24/2020uniQureRaymond JamesInitiated Coverage
7/31/2020uniQureRobert W. BairdUpgrade
6/25/2020uniQureStifel NicolausLower Price Target
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.